Interleukin-5 drives glycolysis and reactive oxygen species-dependent citric acid cycling by eosinophils by Jones, Nicholas et al.
                          Jones, N., Vincent, E. E., Felix, L. C., Cronin, J. G., Scott, L. M., Hole,
P. S., Lacy, P., & Thornton, C. A. (2019). Interleukin-5 drives
glycolysis and reactive oxygen species-dependent citric acid cycling
by eosinophils. Allergy. https://doi.org/10.1111/all.14158
Peer reviewed version
Link to published version (if available):
10.1111/all.14158
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Wiley at https://onlinelibrary.wiley.com/doi/10.1111/all.14158. Please refer to any applicable terms of use of
the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the





Title: Interleukin-5 drives glycolysis and reactive oxygen species-dependent citric acid 
cycling by eosinophils 
 
Authors: Nicholas Jones1, Emma E. Vincent 2,3, Lindsey C. Felix4, James G. Cronin1, 
Louis M. Scott1, Paul S. Hole5, Paige Lacy4 and Catherine A. Thornton1,* 
 
Affiliations: 1Institute of Life Science, Swansea University Medical School, Swansea, 
SA2 8PP, United Kingdom. 2MRC Integrative Epidemiology Unit, University of 
Bristol, Oakfield House, Bristol, BS8 2BN, United Kingdom. 3Cellular and Molecular 
Medicine, University of Bristol, Biomedical Sciences Building, Bristol, BS8 1TD, 
United Kingdom. 4Alberta Respiratory Centre (ARC), Department of Medicine, 
University of Alberta, Edmonton, Alberta, T6G 2G3 Canada. 5Department of 
Haematology, Division of Cancer and Genetics, School of Medicine, Cardiff University, 
Cardiff, CF14 4XN, United Kingdom. 
 
        * Corresponding author: Professor Cathy Thornton 
                                    Swansea University Medical School 
                                    Singleton Park 
                                    Swansea 
                                    SA2 8PP 
                                                E-mail: c.a.thornton@swansea.ac.uk 
                                                Telephone: +44 (0) 1792 602122. 
 
Running title: IL-5 drives the eosinophil metabolic response 
 













Introduction: Eosinophils have been long implicated in anti-parasite immunity and 
allergic diseases and, more recently, in regulating adipose tissue homeostasis. The 
metabolic processes that govern eosinophils, particularly upon activation, are unknown.  
 
Methods: Peripheral blood eosinophils were isolated for analysis of metabolic 
processes using extracellular flux analysis and individual metabolites by stable isotope 
tracer analysis coupled to gas chromatography-mass spectrometry following treatment 
with IL-3, IL-5 or granulocyte-macrophage colony-stimulating factor (GM-CSF). 
Eosinophil metabolism was elucidated using pharmacological inhibitors.  
 
Results: Human eosinophils engage a largely glycolytic metabolism but also employ 
mitochondrial metabolism. Cytokine stimulation generates citric acid cycle (TCA) 
intermediates from both glucose and glutamine revealing this previously unknown role 
for mitochondria upon eosinophil activation. We further show that the metabolic 
program driven by IL-5 is dependent on the STAT5/PI3K/Akt signalling axis and that 
nicotinamide adenine dinucleotide phosphate oxidase (NOX)-dependent ROS 
production might be a driver of mitochondrial metabolism upon eosinophil activation.  
 
Conclusion: We demonstrate for the first time that eosinophils are capable of metabolic 
plasticity, evidenced by increased glucose-derived lactate production upon ROS 
inhibition. Collectively this study reveals a role for both glycolysis and mitochondrial 
metabolism in cytokine-stimulated eosinophils. Selective targeting of eosinophil 
metabolism may be of therapeutic benefit in eosinophil-mediated diseases and 
regulation of tissue homeostasis.  
 
 






Human eosinophils reside primarily in haematopoietic and mucosal tissues. Interest in 
eosinophil activity stems predominantly from their role in anti-parasite immunity and 
allergic disease1-5 but there is growing interest in their role in tissue homeostasis, 
especially adipose tissue6. Eosinophil-mediated effector function involves 
degranulation, the release of antimicrobial cytotoxic molecules, and the respiratory 
burst2 yet we know little about the immunometabolic processes that underpin these 
activities. Activation of other granulocyte populations such as neutrophils and mast 
cells enhances glycolysis to support biosynthetic intermediate production and rapid 
ATP generation7,8. Eosinophil metabolism is assumed to be largely homologous to that 
of neutrophils, where, despite the presence of mitochondria, energy production stems 
primarily from glycolysis5,9,10.  
 
Non-metabolic roles for mitochondria within eosinophils have been the focus of several 
investigations. Mitochondrial DNA can be released in a ‘catapult-like’ fashion from 
eosinophils and contributes to antibacterial defence, although this remains controversial 
and has yet to be confirmed11,12. Furthermore, the initiation of apoptosis has been 
reported as an alternative role to respiration for eosinophil mitochondria10. As 
eosinophils produce large amounts of nicotinamide adenine dinucleotide phosphate 
oxidase (NOX)2-dependent extracellular reactive oxygen species (ROS) upon 
activation13-15, it is commonly thought that oxygen consumption by eosinophils 
supports ROS production rather than oxidative phosphorylation (OXPHOS). Contrary 
to this, human eosinophils are sensitive to oligomycin (mitochondrial ATP synthase 
inhibitor), suggesting that in addition to glycolysis, mitochondria can indeed contribute, 
at least in part, to ATP production5. As such, the role of the mitochondria in eosinophils 
remains unclear and requires investigation.  
 
Glycolysis has been reported to be the main source of ATP in numerous cell types16-18. 
This is especially true for immune cells such as T cells and mast cells, which undergo 
a glycolytic switch upon activation to support rapid ATP production19,20. Little is 
known about the role of glycolysis in eosinophil-mediated immunity, but glycolysis-
derived ATP is essential for the removal of schistosomula by human eosinophils21 and 
cytokines such as IL-3, IL-5, granulocyte-macrophage colony-stimulating factor (GM-




IL-3, IL-5, and GM-CSF, produced primarily by T cell subsets, fibroblasts, and 
epithelial cells, are critical for eosinophil activation and maturation2. Differential 
effects of IL-3, IL-5, and GM-CSF have been identified, with IL-3 generally being a 
weaker inducer of eosinophil activation than either IL-5 or GM-CSF; IL-3 induces less 
glucose uptake, superoxide production and eosinophil-derived neurotoxin (EDN) 
release than IL-5 or GM-CSF22,23. However, IL-3 can prolong ribosomal protein S6 
signalling compared to IL-5 and GM-CSF, producing augmented levels of semaphorin-
7A and heightened protein translation24. Despite these differences in responses of 
eosinophils to IL-3, IL-5, and GM-CSF, the impact of these cytokines on human 
eosinophil metabolic adaptation that underpins these different functional outcomes has 
not been studied.  
 
Here, for the first time, we demonstrate that human eosinophils are metabolically plastic 
cells, up-regulating both glycolytic and TCA cycle intermediates upon activation. We 
show that IL-3, IL-5 and GM-CSF all increase glycolysis and importantly, that upon 
activation by these cytokines, eosinophils increase glutaminolysis and subsequent TCA 
cycling. This is significant as these cells were previously thought to not engage their 
mitochondria for metabolic purposes. In contrast to earlier studies10, we report that the 
IL-5-induced metabolic switch initiates glycolysis and enhances mitochondrial 
respiration in a mechanism that is dependent on the STAT5/PI3K/Akt axis. Finally, the 
ability of esoinophils to compensate for inhibition of ROS production and the 
associated reduced levels of TCA cycle intermediates by increased aerobic glycolysis 















Materials and Methods 
Human eosinophil isolation 
Human peripheral blood was collected from both male (n = 9) and female donors (n = 
25) aged between 18-70 years into heparinised VacuettesTM (Greiner Bio-one, 
Frickenhausen, Germany). We recruited both atopic and non-atopic donors with 
eosinophils comprising between 1-8% of total circulating leukocytes. Specific donor 
demographics can be found in supplementary table 1. All samples were collected with 
informed written consent and ethical approval was obtained from Wales Research 
Ethics Committee 6 (13/WA/0190). Eosinophils were isolated by negative selection 
using immunomagnetic microbeads (autoMACS; Miltenyi Biotec, Cologne, Germany). 




























Eosinophils increase glycolysis in response to cytokines 
In human eosinophils, IL-3, IL-5, and GM-CSF are the predominant cytokines 
associated with their activation25. Therefore, the effect of IL-3, IL-5 and GM-CSF on 
eosinophil metabolism was investigated.  
 
First, we investigated the mode of glucose transport in eosinophils. Gene expression 
levels of the main glucose transporters (GLUT1-4; SLC2A1-4) were determined using 
qPCR. While there was donor variability, GLUT1 (SLC2A1) and GLUT3 (SLC2A3) 
were expressed by all donors (Figure 1A). GLUT4 (SLC2A4) expression was not 
detected, and only some donors expressed detectable GLUT2 (SLC2A2; 3/7) (Figure 
1A). Uptake of a fluorescent glucose analogue 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-
yl)amino)-2-deoxyglucose (2-NBDG) did not differ between unstimulated and 
cytokine-stimulated eosinophils (Figure 1B).  
 
To further investigate the induction of glycolysis upon activation in eosinophils, we 
performed extracellular flux analysis measuring the extracellular acidification rate 
(ECAR) upon treatment with IL-3, IL-5, or GM-CSF. Eosinophils were starved of 
glucose, treated with cytokine followed by the reintroduction of glucose, then addition 
of the ATP synthase inhibitor oligomycin, with a final addition of 2-deoxy-D-glucose 
(2-DG) to arrest glycolysis over the timeline shown in Figure 1C. Here we discovered 
that after a period of glucose starvation, IL-5 or GM-CSF treatment increased ECAR 
significantly in comparison to either the control or IL-3-treated cells (Figure 1C-D). As 
there are multiple sources of acidification that may contribute to ECAR in eosinophils26-
28, we performed stable isotope tracer analysis (SITA) to determine the fate of glucose-
derived carbon atoms upon eosinophil activation. Eosinophils were activated with IL-
3, IL-5 or GM-CSF in the presence of 13C6-glucose for 4 h. If eosinophil metabolism is 
largely homologous to that of neutrophils29, i.e. glycolytic, then it would be expected 
that the majority of labelled carbon would be present as the m+3 mass isotopologue of 
lactate produced from the m+3 mass isotopologue of pyruvate (Figure 1E). These data 
demonstrate that IL-3, IL-5, or GM-CSF treatment promotes the incorporation of 13C 
atoms into pyruvate (Figure 1F-G) and lactate (Figure 1H-I). We also observed 13C 
labelled extracellular lactate within the supernatant (Figure 1J), excess production of 




Collectively the data demonstrate that eosinophils treated with IL-3, IL-5 or GM-CSF 
switch to a glycolytic metabolism.  
 
Cytokine-stimulated eosinophils consume oxygen for ROS production 
It has been reported that eosinophils do not require their mitochondria for ATP 
production via OXPHOS10,30. However, mitochondria are diverse organelles with 
multiple metabolic roles. We confirmed the presence of mitochondria using 
transmission electron microscopy (Figure 2A). Mitochondrial function was assessed by 
measuring oxygen consumption rate (OCR) in the presence of IL-3, IL-5 or GM-CSF 
(Figure 2B). Baseline OCR was increased in IL-5 and GM-CSF treated cells post-
glucose starvation compared to the control and IL-3-treated cells (Figure 2C). We noted 
a decrease in OCR upon oligomycin treatment under all conditions, this is indicative of 
oxygen consumption for ATP generation, which is in agreement with a previous study5. 
Increasing the concentration of IL-3 delivered to the cells caused an increase in both 
ECAR and OCR (50 and 100 ng/mL; Figure 2D-E) suggestive of a differential kinetic 
response of eosinophils to IL-3 versus IL-5/GM-CSF. 
 
In our experiments, eosinophils clearly consume oxygen, especially in response to 
treatment with IL-5 or GM-CSF. However, oxygen consumption can occur 
independently of OXPHOS for processes such as respiratory burst, involving the 
generation of ROS and subsequently hydrogen peroxide via NOX enzymes13,14. To 
determine whether any of the cytokine-induced oxygen consumption was due to 
mitochondrial ROS production, we utilised the mitochondrial superoxide indicator 
MitoSOX and selected a time point to coincide with the extracellular flux assay (15 
minutes). Regardless of the cytokine used for stimulation, mitochondria did not 
contribute to oxygen consumption via ROS production at the time point measured; 
rotenone was used as a positive control (Figure 2F-G).  
 
To further investigate increased oxygen consumption upon stimulation we investigated 
whether IL-3, IL-5 and GM-CSF induce total ROS production. We determined total 
oxidative stress levels using the fluorescent probe CellROX and flow cytometry, 
phorbol 12-myristate 13-acetate (PMA) was used as a positive control. All three 
cytokines induced ROS production in comparison to the CellROX control with GM-




(DPI), these responses were shown to be NOX-dependent, although this was only 
significant for GM-CSF and PMA-induced ROS production. These data raise the 
question of what happens to OCR when ROS production is inhibited, and we have 
addressed this in relation to IL-5 later in the manuscript, see Figure 5. 
 
Cytokine-stimulated eosinophils synthesise TCA cycle intermediates 
In addition to the generation of ATP and ROS, mitochondria can act as a biosynthetic 
hubs, synthesising TCA cycle intermediates and non-essential amino acids, however 
this has not been previously demonstrated in eosinophils. To test this, eosinophils were 
activated with IL-3, IL-5, or GM-CSF in the presence of 13C6-glucose for 4 h. Upon 
activation, eosinophils incorperated 13C-glucose into TCA cycle intermediates, such as 
citrate, succinate, malate and fumarate (Figure 3A-E). The metabolite pools analysed 
were mostly composed of  the unlabelled (m+0) or m+2 mass isotopologue (Figure 3F; 
Supplementary Figure 1A-C) indicating lack of sustained TCA cycling.  
 
Next, we determined whether TCA cycle intermediates are used as precursors for the 
synthesis of non-essential amino acids. Glutamate abundance was increased upon 
eosinophil stimulation with IL-3, IL-5 or GM-CSF (Figure 3G) and was largely present 
as the m+2 mass isotopologue (Figure 3H). While the eosinophils demonstrated 
production of glutamine and aspartate at baseline, cytokine stimulation had no further 
effect on the production of these. However, in comparison to the untreated control, 
cytokine-stimulated eosinophils had a reduced pool of 12C unlabelled amino acids, 
indicating consumption of these amino acids (Supplementary Figure 2A-D).  
 
Fully functional canonical TCA cycling requires two metabolite inputs: acetyl-CoA 
derived primarily from glucose and α-ketoglutarate derived from glutamine 
(Supplementary Figure 3A). Having established that eosinophils incorporate 13C-
glucose into TCA cycle intermediates, we next wanted to determine whether cytokine-
activated eosinophils engage glutaminolysis. To address this, eosinophils were 
activated with IL-3, IL-5 or GM-CSF in the presence of 13C-glutamine for 4 h. 
Incorporation of 13C into TCA intermediates was increased in IL-3, IL-5 or GM-CSF 
treated eosinophils compared to the untreated controls (Supplementary Figure 3B).  
 




The development and clinical implementation of IL-5 targeting therapies in the 
treatment of asthma31 prompted us to consider the early signalling mechanisms that 
govern increased ECAR and OCR in response to IL-5 treatment. STAT5 is activated 
upon IL-3, IL-5 or GM-CSF ligation32,33, and in certain circumstances can be activated 
by ROS production via the common β chain34. We initially confirmed STAT5 
phosphorylation in eosinophils treated with IL-3, IL-5 and GM-CSF. All cytokines 
induced STAT5 phosphorylation, but this only reached significance above baseline for 
IL-5 and GM-CSF (Figure 4A). Next, we wanted to determine whether inhibition of 
STAT5 affected the immediate ECAR and OCR responses of eosinophils treated with 
IL-5. Pre-treatment with the STAT5 inhibitor Nʹ-((4-oxo-4H-chromen-3-
yl)methylene)nicotinohydrazide (STAT5i) completely abrogated the ECAR and OCR 
response in IL-5-stimulated eosinophils (Figure 4B-C). Calculations of ‘pre-cytokine’ 
and ‘post-cytokine’ data can be found at Supplementary Figure 4. 
 
In addition to cytokine-mediated STAT5 activation, both IL-5 and ROS can activate 
the PI3K/Akt axis34, therefore we next investigated the role of PI3K/Akt in human 
eosinophil metabolism. Treatment with either the PI3K inhibitor LY294002 or the 
Akt1/2 inhibitor, abrogated IL-5 stimulated induction of ECAR (Figure 4D). The same 
trend was observed for OCR whereby the PI3K inhibitor reduced the immediate 
induction of OCR in eosinophils treated with IL-5 (Figure 4E). However, treatment 
with the Akt1/2 inhibitor did not reduce IL-5 induced OCR (Figure 4E), suggesting 
other downstream PI3K pathways may be involved. These data show that one of the 
key immediate effects of IL-5 on eosinophils is up-regulation of glycolysis and this is 
dependent on the STAT5/PI3K/Akt axis. 
 
ROS inhibition reduces TCA cycling of IL-5 stimulated eosinophils 
To determine if the observed cytokine-stimulated metabolic changes in eosinophils 
were promoted by ROS production we next determined whether NOX had a role in 
increased ECAR and OCR with a focus on IL-5 as before. Bioenergetic analyses were 
used to show that DPI had no effect on IL-5-stimulated glycolysis (Figure 5A) but 
significantly reduced peak OCR (Figure 5B). SITA using 13C-glucose showed 
increased incorporation of 13C into pyruvate and lactate (indicated as an increased m+3 
mass isotopologue) in the presence of DPI (Figure 5C-D). This was accompanied by a 




represented by a decreased abundance of the m+2 mass isotopologue (Figure 5F). DPI 
treatment negatively impacted on the synthesis of amino acids glutamate and aspartate, 
from 13C-glucose, by reducing 13C incorporation and the m+2 mass isotopologue 
(Figure 5G-H). Collectively these data demonstrate that NOX-mediated ROS may have 


































The study of eosinophil metabolism has been challenging, but recent years have seen 
the introduction of novel, refined technologies that allow metabolic analyses on low 
cell numbers with more sensitive readouts. This has been driven by the burgeoning field 
of immunometabolism and the increasingly recognised role of cellular metabolism in 
immune cell fate and function. Cellular metabolism through energy production (ATP) 
and biosynthetic intermediate generation orchestrates numerous effector roles such as 
cytokine production, migration and proliferation and can have a profound impact on 
various human pathologies35. Aside from their well-recognised energetic and 
biosynthetic roles, individual metabolites can have alternative roles. For example, TCA 
cycle metabolites, succinate and fumarate act as inflammatory signalling molecules. In 
LPS-stimulated macrophages, succinate stabilizes hypoxia-inducible factor-1α to 
promote increased glycolysis and IL-1β production9,36,37. Therefore, elucidating the 
cellular metabolic response of eosinophils not only improves our basic understanding 
of eosinophil function, especially how it might apply to tissue homeostasis, but has 
implications for revealing immunopathogenic and therapeutic strategies in eosinophilic 
disorders.  
 
The rapid engagement of aerobic glycolysis by eosinophils in response to cytokines 
demonstrated here was accompanied by accumulation of both intra- and extracellular 
lactate. Lactate creates an acidic environment in which eosinophils are known to thrive, 
such as in the lung38. Furthermore, excess lactate retains T cells in pro-inflammatory 
environments, curtailing their migration39. If the same occurred for eosinophils this 
would provide a mechanism to retain viable eosinophils in an acidic inflammatory 
tissue environment. This increased glycolytic rate that supports the accumulation of 
lactate is presumably due to either GLUT1 or GLUT3 mediated glucose uptake as these 
transporters were expressed by all donors, or through kinetic effects on the direct 
phosphorylation of glycolytic enzymes22. 
 
A key feature of the work presented here is clarity surrounding the role of mitochondria 
in eosinophil metabolism. It is well established that eosinophils utilise their 
mitochondria for apoptotic purposes10,30, however definitive metabolic contributions 
have remained elusive. Here, we confirmed that cytokine-stimulated eosinophils were 




mitochondria in eosinophils have an important role in mediating metabolic responses 
to cytokines which is in agreement with a previous study5.  
 
Whilst the conversion of glucose to lactate seems to be the predominant metabolic 
pathway in response to cytokine stimulation, we used stable isotope tracing to show 
that eosinophils use both glucose and glutamine to generate TCA cycle intermediates 
and support OXPHOS upon activation. To our knowledge we are the first to provide 
evidence that carbons from glucose and glutamine are incorporated into TCA 
metabolites upon cytokine stimulation in eosinophils. Collectively, we reveal a novel 
role for human eosinophil mitochondria that extends beyond apoptosis and antibacterial 
defence. We demonstrate that eosinophils can utilise their mitochondria for TCA 
cycling contributions to OXPHOS and biosynthesis of amino acids. In support of a role 
for mitochondrial metabolism in eosinophils as we described here, a recent study 
indicated that peripheral blood eosinophils have increased oxidative parameters in 
comparison to neutrophils5. However, this interpretation was based solely on decreased 
oxygen consumption upon exposure to oligomycin and did not definitively characterise 
the metabolic fuels consumed by eosinophils.  
 
The effects of IL-3, IL-5 and GM-CSF on eosinophil metabolism were broadly similar. 
To better understand the signalling processes that govern cytokine-mediated changes 
to eosinophil cellular metabolism we chose to focus on a single cytokine. IL-5 was 
chosen as it is a therapeutic target for treating eosinophilic asthma via monoclonal 
antibodies to IL-5 itself or IL-5R31. IL-5 ligation in human eosinophils has been 
shown to activate the JAK/STAT pathway, specifically STAT540,41. With use of a 
specific STAT5 inhibitor we determined that increases in both ECAR and OCR upon 
IL-5 stimulation were dependent on STAT5 signalling. Because activated eosinophils 
increased their glucose utilization substantially, our attention turned to the PI3K/Akt 
axis as it is known to control glycolysis in other immune cell types such as T cells and 
macrophages42,43. PI3K and Akt inhibitors had a profound effect on the IL-5 mediated 
metabolic switch, especially glycolysis, showing that the IL-5 induced metabolic 
switch in human eosinophils is mediated by the STAT5/PI3K/Akt signalling axis. The 
IL-5 induced OCR was abrogated with PI3K inhibition but not Akt. This suggests that 




consumption, such as the PI3K/Rac pathway44. Respiratory burst in eosinophils has 
been closely linked previously with the Rac pathway, thus offering a plausible 
explanation for our observations15. Elucidating roles of multiple Akt-independent 
downstream PI3K targets and their contributions to eosinophil metabolism warrants 
further investigation.  
 
Finally, we considered the link between ROS production and metabolic pathway 
activity in eosinophils again focussing on the effects of IL-5. Treatment of eosinophils 
with IL-5 has been shown to induce ROS production23 and here we show that IL-5 
increases oxygen consumption. As NOX-dependent respiratory burst is a fundamental 
effector function of eosinophils14 we sought to investigate the role of ROS in eosinophil 
metabolism. Inhibiting NOX-dependent ROS production reduced the abundance of 
TCA cycle intermediates while increasing the accumulation of glucose-derived lactate 
suggesting that ROS may be a driver of eosinophil mitochondria metabolism in 
particular. This highlights that different bioactive molecules in the immediate 
microenvironment of eosinophils shape their metabolic plasticity.  
 
Our study outlines the metabolic requirements of mitochondria in cytokine-activated 
eosinophils. We also show that ROS may enable metabolic plasticity. Taken together, 
this provides further insight into the mechanistic control of eosinophil function. It is 
likely that terminally differentiated cells such as eosinophils do not require extensive 
energy production and biosynthesis to support homeostasis or activation. Instead 
multiple cytokines and important mediators such as eosinophil-derived neurotoxins and 
peroxidases are contained within pre-formed granules. However, cytokine-mediated 
activation clearly up-regulates cytoplasmic and mitochondrial metabolic pathways. 
This raises further questions about the links between eosinophil function and 
metabolism including the bioenergetic demands of piecemeal degranulation and the 
effects of mitochondrial DNA release on the metabolic status of eosinophils. 
Eosinophils are a characteristic feature of type 2 immune responses linked to 
immunopathology in asthma and other inflammatory disorders but also to tissue 
defence and repair processes in helminthic parasite infection45 and in other settings 
including metabolic homeostasis in adipose tissue6. Greater understanding of the 
regulation of eosinophil recruitment, retention and survival would provide mechanistic 




other eosinophilic diseases. Cell-specific delivery systems of pharmacological agents 
via for example Siglec-8 could be one route46 or more general approaches to limiting 
lactate in the tissue microenvironment during pathology might have broad effects on 
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Figure 1. IL-3, IL-5 or GM-CSF stimulated eosinophils increase glycolytic 
metabolism and production of lactate. (A) Expression levels of glucose transporters 
(GLUT) 1-4. (B) Representative flow cytometry plot of glucose uptake by eosinophils 
activated for 1 h with IL-3, IL-5 or GM-CSF (10 ng/mL) using probe 2-(N-(7-nitrobenz-
2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG; 100 μM). (C) Glycolytic 
stress profile of eosinophils by measuring extracellular acidification rate (ECAR; 
mpH/min) before and following addition of IL-3, IL-5, GM-CSF (10 ng/mL), glucose 
(5.5 mM), oligomycin (1 μM) and 2-DG (100 mM) at the time points indicated. (D) 
Post-glucose ECAR calculated via the averaged ECAR values from measurement 
points 7-9 minus the averaged ECAR values from measurement points 1-3. (E) 
Schematic of uniformly labelled 13C6-glucose incorporation into pyruvate and lactate. 
Eosinophils were activated with IL-3, IL-5, or GM-CSF (10 ng/mL) for 4 h. (F) 
Relative abundance of 12C and 13C pyruvate. (G) Mass isotopologue distribution (MID) 
of the pyruvate pool. (H) Relative abundance of 12C and 13C lactate including (I) MID 
of the lactate pool. (J) Relative abundance of 12C and 13C extracellular lactate. (K) 
Extracellular lactate production of eosinophils treated with IL-3, IL-5 or GM-CSF (10 
ng/mL) for 4 h. Data are represented as mean ± SEM of 7 (A), 4 (B), 3-5 (C-D, F-I), 2-
3 (J) and 2-4 (K) independent experiments with each data point representing an 
individual donor. Statistical analysis was performed using a one-way ANOVA with 
multiple comparisons to the control group (D, K) or a two-way ANOVA (F-J); * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
 
Figure 2. Cytokine treatment induces mitochondrial-independent ROS 
production (A) Mitochondrial morphology of human eosinophils by TEM. (B) 
Oxidative stress assay measured via oxygen consumption rate (OCR; pmoles/min) 
before and following addition of IL-3, IL-5, GM-CSF (10 ng/mL), glucose (5.5 mM), 
oligomycin (1 μM) and 2-DG (100 mM) at the time points indicated. (C) Percentage 
OCR increase in comparison to baseline. (D) Glycolytic stress and (E) oxidative stress 
IL-3 dose response. Eosinophils were given IL-3 (10, 50 and 100 ng/mL), glucose (5.5 
mM), oligomycin (1 μM) and 2-DG (100 mM) at the time points indicated. (F) 
Representative flow cytometry plot and (G) MitoSOX+ve population of eosinophils 
activated with IL-3, IL-5 or GM-CSF (10 ng/mL) and incubated with MitoSOX for 15 




measured by CellROX from one donor and (I) CellROX+ive population of eosinophils 
stimulated with IL-3, IL-5 or GM-CSF (10 ng/mL) ± DPI (10 μM). Dotted line indicates 
unstimulated controls in the presence of CellROX. Data expressed as mean ± SEM of 
2 (A), 3-5 (B-C), 2 (D-E), 4-5 (G) and 6-8 (I) independent experiments with each data 
point representing an individual donor. Statistical analysis was performed using a one-
way ANOVA with multiple comparisons to the control group (C) or an unpaired t test 
(I); * p ≤ 0.05, *** p ≤ 0.001. 
 
Figure 3. IL-3, IL-5 or GM-CSF treatment induces the production of TCA cycle 
intermediates. (A) Schematic of uniformly labelled 13C6-glucose incorporation into 
TCA cycle intermediates. Eosinophils were activated with IL-3, IL-5 or GM-CSF (10 
ng/mL) for 4 h. Relative abundance of 12C and 13C (B) citrate, (C) succinate, (D) malate 
and (E) fumarate. (F) Mass isotopologue distribution (MID) of m+2 citrate, succinate 
and malate. (G) Relative abundance of 12C and 13C glutamate including the (H) MID 
distribution. All data are from 3-6 independent experiments with each data point 
representing an individual donor. Data expressed as mean ± SEM. Statistical analysis 
was performed using a two-way ANOVA; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
 
Figure 4. The STAT5/PI3K/Akt axis is responsible for the metabolic switch in IL-
5 treated eosinophils. (A) Representative immunoblot of eosinophils treated for 15 
min with IL-3, IL-5 or GM-CSF (10 ng/mL) for pSTAT5694 and β-actin. Corresponding 
densitometry analysis of pSTAT5 normalised to β-actin. (B) ECAR and (C) OCR 
before and following addition of a STAT5 inhibitor (STAT5i; Nʹ-((4-oxo-4H-chromen-
3-yl)methylene)nicotinohydrazide; 100 μM), IL-5 (10 ng/mL) and 2-DG (100 mM), 
including ‘pre-cytokine’ activation and ‘post-cytokine’ activation pooled OCR and 
ECAR data. (D) ECAR and (E) OCR before and following addition of a PI3K inhibitor 
(LY294002; 10 μM) or Akt1/2 inhibitor (1,3-dihydro-1-(1-((4-(6-phenyl-1H-
imidazo[4,5-g]quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one 
trifluoroacetate salt hydrate; 10 μM), IL-5 (10 ng/mL) and 2-DG (100 mM). Data 
expressed as mean ± SEM of 5 (A), 2-3 (B-C) and 4 (D-E) independent experiments 
with each data point representing an individual donor. Statistical analysis was 
performed using a Friedman test with Dunn’s multiple comparisons (A) or a two-way 






Figure 5. DPI inhibits oxidative metabolism in IL-5 stimulated eosinophils. (A) 
ECAR (mpH/min) and (B) OCR (pmoles/min) of eosinophils treated with IL-5 (10 
ng/mL) ± DPI (100 nM), glucose (5.5 mM), oligomycin (1 μM) and 2-DG (100 mM). 
Eosinophils were activated with IL-5 (10 ng/mL) ± DPI (100 nM) for 4 h in the presence 
of 13C-glucose. (C) Relative abundance of 12C and 13C and (D) mass isotopologue 
distribution (MID) of glycolytic intermediates pyruvate and lactate. (E) Relative 
abundance of 12C and 13C and (F) MID of TCA cycle intermediates citrate, succinate, 
fumarate and malate. (G) Relative abundance of 12C and 13C and (H) MID of amino 
acids glutamate and aspartate. Data expressed as mean ± SEM of 4 (A-B) and 3 (C-H) 
independent experiments with each data point representing an individual donor. 
Statistical analysis was performed using an unpaired t test (B) or a two way ANOVA 
(C-H); * p ≤ 0.05, ** ≤ p 0.01, *** p ≤ 0.001. 
